Stockscreener 앱 받기
8.91
4.81%
-0.45
시간 외 거래:
9.09
0.18
+2.02%
Anavex Life Sciences Corporation 주식(AVXL)의 최신 뉴스
Envestnet Asset Management Inc. Purchases 20,771 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Head-To-Head Comparison: Anavex Life Sciences (NASDAQ:AVXL) vs. Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
Taking on analysts’ expectations and winning: Anavex Life Sciences Corporation (AVXL) - Sete News
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by JPMorgan Chase & Co. - Defense World
Anavex Life Sciences' Schizophrenia Clinical Study Completes Enrollment - marketscreener.com
Anavex Life Sciences Corporation (AVXL) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - The Manila Times
Anavex Life Sciences Corporation [AVXL] Records 50-Day SMA of $8.86 - knoxdaily.com
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference | AVXL Stock News - GuruFocus
Anavex Showcases Breakthrough CNS Drug Portfolio: CEO Details Multiple Disease Targets at Citizens Conference - Stock Titan
Wells Fargo & Company MN Decreases Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Anavex Life Sciences Corporation’s Market Journey: Closing Strong at 9.31, Up 1.09 - DWinneX
Buying Buzz: Anavex Life Sciences Corporation [AVXL] Director Donhauser Peter D.O. purchases 2,835 shares of the company – Knox Daily - knoxdaily.com
AVXL overperforms with a 5.14 increase in share price - uspostnews.com
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board - The Manila Times
Harvard-Trained Alzheimer's Pioneer With 35,000-Patient Database Strengthens Anavex's Scientific Team - Stock Titan
Anavex Life Sciences Appoints Dr. Audrey Gabelle, MD, PhD To Scientific Advisory Board - citybiz
Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer's Data ... - Yahoo Finance
Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer’s Data ... By GuruFocus - Investing.com Canada
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by LPL Financial LLC - Defense World
Anavex Life Sciences Presents Novel Alzheimer Treatment Research at International Conference in Abu Dhabi - Nasdaq
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East - TradingView
Geode Capital Management LLC Has $20.14 Million Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corp. (NASDAQ:AVXL) Holdings Raised by Alliancebernstein L.P. - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences LawsuitAVXL - ACCESS Newswire
Anavex Stock Jumps Pre-Market After Submitting Oral Alzheimer's Drug To European Regulators For Approval: Retail Over The Moon - MSN
Wellington Management Group LLP Makes New $1.70 Million Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Raymond James Financial Inc. Acquires Shares of 15,584 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Prudential Financial Inc. Acquires Shares of 10,160 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Vanguard Group Inc. Sells 59,727 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Corebridge Financial Inc. Trims Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Four-Year Data on New Drug for Early AD Positive - streetwisereports.com
Biotech Company Finds High-Impact Alzheimer's Therapy in Europe - streetwisereports.com
Anavex Life Sciences (NASDAQ:AVXL) Given Buy Rating at HC Wainwright - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at D. Boral Capital - Defense World
Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years - Benzinga
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease - The Manila Times
Breakthrough: New Alzheimer's Drug Cuts Cognitive Decline Over 4 Years in Clinical Trial - Stock Titan
Class Action Filed Against Anavex Life Sciences Corporation (AVXL) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Anavex Life Sciences Corporation (AVXL)May 13, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact Levi & Korsinsky about pending Class ActionAVXL - ACCESS Newswire
AVXL’s price-to-free cash flow ratio: What it means for investors - uspostnews.com
Commonwealth Equity Services LLC Buys 7,285 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at HC Wainwright - Defense World
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Anavex Showcases Breakthrough CNS Therapies: CEO Details Pipeline at Major Healthcare Conference - Stock Titan
Heartland Advisors Inc. Takes Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat
19,558 Shares in Anavex Life Sciences Corp. (NASDAQ:AVXL) Acquired by Proficio Capital Partners LLC - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Trading Down 3.2%Here's Why - MarketBeat
AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Purchased by Intech Investment Management LLC - The AM Reporter
Charles Schwab Investment Management Inc. Purchases 11,239 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Bank of New York Mellon Corp Has $2.37 Million Stock Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors With Losses to Inquire About Securities Class Action Investigation – AVXL - Business Wire
0.39%
3.66%
자본화:
|
볼륨(24시간):